fluorescein has been researched along with n-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl)benzamide in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ito, S; Kitano, T; Kojima, H; Mabuchi, T; Matsumura, S; Minami, T; Nagano, T; Okuda-Ashitaka, E | 1 |
1 other study(ies) available for fluorescein and n-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl)benzamide
| Article | Year |
|---|---|
Attenuation of neuropathic pain by the nociceptin/orphanin FQ antagonist JTC-801 is mediated by inhibition of nitric oxide production.
Topics: Aminoquinolines; Animals; Benzamides; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Fluorescein; Fluorescence; Fluorescent Dyes; Functional Laterality; Glutamic Acid; Hyperalgesia; In Vitro Techniques; Male; Mice; Mice, Knockout; NADPH Dehydrogenase; Neuralgia; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Nociceptin; Opioid Peptides; Peptide Fragments; Reaction Time; Spinal Cord; Spinal Cord Injuries; Time Factors | 2003 |